Somatostatin Receptors

MK-1421 is a potent and selective antagonist of the somatostatin receptor type 3 (sstr3). By inhibiting sstr3, MK-1421 plays a significant role in the modulation of insulin secretion, making it a valuable tool in research related to type 2 diabetes. Its specificity and efficacy make it suitable for investigating the complex pathways involved in metabolic disorders.

[D-Trp8,Tyr11] Somatostatin is a somatostatin analogue that enhances the hormone's stability and bioactivity. This compound is known to inhibit the secretion of growth hormone and other hormones, making it valuable in studies related to hormonal regulation and physiological processes. Applications include endocrynology research and the investigation of tumor growth inhibition, particularly in neuroendocrine tumors.

[Tyr12] Somatostatin 28 (1-14) is an analogue of Somatostatin-28 (1-14) that targets somatostatin receptors to modulate neuropeptide signaling. This peptide fragment plays a crucial role in the regulation of various physiological processes, including hormone secretion and cell proliferation. It is commonly used in research applications focused on neuroendocrine signaling pathways and therapeutic interventions for endocrine-related disorders.

SSTR4 Agonist 3 is a selective agonist for the somatostatin receptor subtype 4 (SSTR4), which is primarily expressed in the hippocampus and neocortex, areas implicated in memory and learning. This compound demonstrates significant biological activity in rodent models, exhibiting anti-nociceptive and anti-inflammatory effects that are relevant to both acute and chronic pain conditions. SSTR4 Agonist 3 holds potential for further research into pain modulation and Alzheimer's disease pathology.

[D-Trp8] Somatostatin-14 is a tetradecapeptide analog of somatostatin that exhibits enhanced potency compared to its native counterpart. This compound primarily targets somatostatin receptors, influencing various physiological processes including hormonal secretion and cell proliferation. It is utilized in research applications focusing on neuroendocrine regulation and the therapeutic potential of somatostatin analogs in treating conditions such as acromegaly and neuroendocrine tumors.

Octreotide dimer (parallel) is a parallel dimer of Octreotide, a synthetic octapeptide that acts as an agonist of somatostatin receptors. This compound exhibits potent inhibitory effects on hormone secretion, making it valuable for research in neuroendocrine tumors and diagnostic imaging. Octreotide dimer (parallel) is employed in studies exploring endocrine regulation and potential therapeutic applications in various somatostatin receptor-related disorders.

AP102 is a dual somatostatin receptor analogue targeting SSTR2 and SSTR5. This disulfide-bridged octapeptide exhibits subnanomolar affinity for SSTR2 and SSTR5, with IC50 values of 0.63 nM and 0.65 nM, respectively, while showing no binding to SSTR1 or SSTR3. AP102 is particularly valuable in research related to acromegaly and neuroendocrine tumors, providing insights into receptor-specific signaling pathways.

(1R,1'S,3'R/1R,1'R,3'S)-L-054,264 is a selective non-peptide agonist for the human somatostatin receptor subtype 2 (sst2). This compound is instrumental in investigating the role of sst2 in retinal neuromodulation, making it valuable for research on neurobiology and related therapeutic applications. Its unique selectivity allows for precise modulation of receptor activity, facilitating studies on somatostatin-mediated pathways.

L-803087 TFA is a potent and selective agonist of the somatostatin sst4 receptor, exhibiting a Ki value of 0.7 nM. Demonstrating over 280-fold selectivity for the sst4 receptor compared to other somatostatin receptors, L-803087 TFA enhances AMPA-mediated synaptic responses in the hippocampus. This compound is also noted for its role in increasing kainate-induced seizures in murine models, making it valuable for research into neurophysiological processes and receptor signaling mechanisms.

SST1 receptor antagonist-2 is a piperazine derivative that selectively inhibits somatostatin receptor 1 (SST1). This compound displays significant potential in the investigation of psychiatric disorders, neurodegenerative diseases, tumors, vascular conditions, and immunological diseases. Its selective antagonism of SST1 may provide insights into various pathological processes and therapeutic strategies.

Branosotine is a potent agonist of the somatostatin receptor subtype 2 (SSTR2), exhibiting an EC50 of less than 0.1 nM. This compound demonstrates significant biological activity in modulating neuroendocrine signaling pathways, making it a valuable tool for research involving neuropsychiatric disorders and hormonal regulation. Its high specificity and efficacy position Branosotine as an important reagent for studying SSTR2-related biological processes.

Zavolosotine is an orally active agonist of the somatostatin receptor type 5 (SST5), exhibiting a potent EC50 of less than 1 nM. This compound effectively inhibits insulin and glucagon secretion while also elevating glucagon levels in a rat model. Zavolosotine is valuable for research in glucose metabolism and endocrine signaling pathways, making it a key reagent for studies on metabolic disorders and diabetes.

Mazisotine tartrate is a potent SSTR4 agonist that selectively activates the somatostatin receptor subtype 4. This compound is primarily involved in modulating neuroendocrine functions and has potential applications in the study of metabolic disorders, neuroprotection, and cancer therapy. Its biological activity suggests utility in investigating signaling pathways linked to this receptor subtype, making it a valuable tool for research in endocrinology and related fields.

SSTR5 Antagonist 3 is a potent inhibitor targeting the somatostatin receptor subtype 5 (SSTR5) with IC50 values of 2.8 nM in human tissues and 1.4 nM in mouse models. This orally bioavailable compound exhibits low hERG inhibition, making it suitable for in vivo studies. SSTR5 Antagonist 3 is primarily utilized in research focusing on anti-gallstone therapies and the modulation of related gastrointestinal functions.

BIM-23027 is a selective agonist of the sst2 receptor, exhibiting an EC50 of 0.32 nM. This compound mimics the action of somatostatin (SRIF), a cyclic tetradecapeptide, and plays a critical role in stimulating dopamine release through a Glu-dependent mechanism. BIM-23027 is suitable for research applications focusing on neuroendocrine regulation and receptor pharmacology.

Somatostatin-25 is a naturally occurring neuropeptide hormone that primarily inhibits the secretion of growth hormone. This regulatory activity plays a crucial role in various physiological processes, including the modulation of endocrine functions and gastrointestinal activities. It is widely utilized in research to investigate growth hormone regulation and its implications in disorders related to endocrine signaling.

Tyr-Somatostatin-28 is a potent somatostatin analog featuring a tyrosine residue at the N-terminus. This modification enhances its stability and bioactivity, making it an important tool for studying somatostatin receptor interactions and signaling pathways. Tyr-Somatostatin-28 has applications in neurobiology and endocrinology research, particularly in the investigation of hormone regulation and therapeutic targets for diseases such as acromegaly and neuroendocrine tumors.

DOTAMTATE is a somatostatin analogue that selectively targets somatostatin receptors. It exhibits significant potential for the imaging and treatment of somatostatin receptor-positive neuroendocrine tumors, making it a valuable tool for investigative research in oncology and radiopharmaceutical applications. The incorporation of 212Pb into DOTAMTATE enhances its therapeutic efficacy and suitability for targeted radionuclide therapy.